Critical Comparison: Senestech (NASDAQ:SNES) vs. Haemonetics (NYSE:HAE)

Senestech (NASDAQ:SNES) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Volatility & Risk

Senestech has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Valuation and Earnings

This table compares Senestech and Haemonetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$1.86 million	5.61	-$6.18 million	($3.65)	-0.55
Haemonetics	$1.36 billion	2.37	$167.68 million	$3.42	20.13

Haemonetics has higher revenue and earnings than Senestech. Senestech is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Senestech and Haemonetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1	1	0	1	2.33
Haemonetics	1	3	7	1	2.67

Haemonetics has a consensus price target of $84.40, indicating a potential upside of 22.60%. Given Haemonetics’ stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than Senestech.

Institutional & Insider Ownership

5.2% of Senestech shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 5.3% of Senestech shares are owned by insiders. Comparatively, 1.8% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Senestech and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senestech	-253.54%	-98.35%	-73.17%
Haemonetics	12.67%	27.22%	9.52%

Summary

Haemonetics beats Senestech on 12 of the 14 factors compared between the two stocks.

About Senestech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.